Table 6.
DN4 (Douleur Neuropathique score 0–10) in the three study groups (DEX group: dexmedetomidine, LIDO group: lidocaine and CONTROL group: normal saline) at 3, 6, and 12 months
| Group | DN4 | |||
|---|---|---|---|---|
| Mean ± SD | p value (DEX-CONTROL) | p value (LIDO-CONTROL) | p value (DEX-LIDO) | |
| DN4 3 months | ||||
| LIDO | 1.60 ± 1.73 | 0.54 | 0.88 | 1.00 |
| DEX | 1.33 ± 1.49 | |||
| CONTROL | 2.24 ± 2.20 | |||
| DN4 6 months | ||||
| LIDO | 0.92 ± 1.19 | 0.57 | 0.69 | 1.00 |
| DEX | 0.83 ± 1.17 | |||
| CONTROL | 1.72 ± 1.99 | |||
| DN4 12 months | ||||
| LIDO | 0.40 ± 0.76 | 0.78 | 0.50 | 1.00 |
| DEX | 0.58 ± 1.10 | |||
| CONTROL | 1.32 ± 1.91 | |||
Values are expressed as mean ± standard deviation (SD)
*Statistical significance (p < 0.05)